Archaeological and Geomorphological Investigations at the Proposed Greenbelt Project, Des Moines, Iowa. Phase 2

1991 ◽  
Author(s):  
James S. Ross ◽  
Jane K. Johnston ◽  
Jeffrey D. Anderson ◽  
Michael J. McNerney ◽  
Mary R. McCorvie
Keyword(s):  
Phase 2 ◽  
2019 ◽  
Vol 97 (Supplement_2) ◽  
pp. 229-230
Author(s):  
Peter J Lammers ◽  
Chad A Stahl ◽  
Mark S Honeyman

Abstract A 2 × 2 × 2 factorial design was used to compare the effect of SID Lys:ME concentration (current vs. reduced), stocking density (1.30 vs. 4.05 m2/pig), and harvest month (August vs. March) on pigs raised in bedded hoop barns in Western Iowa. For each harvest month, 420 pigs produced from the mating of Duroc boars (Choice Genetics; West Des Moines, IA) to Camborough females (PIC; Hendersonville, TN) were sorted into 12 pens. Six pens were inside 3 large-scale (9.1 × 18.3 m) hoop barns and were stocked with 64 pigs/pen (32 barrows and 32 gilts; 1.30 m2/ pig). Six pens were inside 3 small-scale (6.0 × 10.8 m) hoop barns and were stocked with 6 pigs/pen (3 barrows and 3 gilts; 4.05 m2/pig). Within each stocking density, pens were randomly assigned to 1 of 2 diets which were fed in 2 phases. Corn-soybean meal diets were formulated to deliver 2.94 or 2.34 g SID Lys per Mcal ME in phase 1 (72.6–95.0 kg) and 2.34 or 1.76 g SID Lys per Mcal ME in phase 2 (> 95.0 kg). Pigs were individually weighed every 28 days and feed disappearance was recorded. When pigs in a pen averaged 129.3 kg the entire pen of pigs were harvested. A single chop (last-rib location; 2.54 cm thick) was collected from each carcass to assess pork quality. Pigs harvested in the summer grew faster, more efficiently, and with more intramuscular fat than those harvested in winter (P-value ≤ 0.05) but had lower 10th rib pH (P-value < 0.0001). Pigs allotted 4.05 m2/pig grew more efficiently but had reduced last rib pH as compared to pigs stocked at 1.30 m2/pig (P-value < 0.05). Reducing SID Lys:ME did not impact growth performance or carcass characteristics (P-value > 0.10). Lower concentrations of SID Lys:ME may be adequate for pigs housed in bedded hoop barns but further study is warranted.


2019 ◽  
Vol 97 (Supplement_2) ◽  
pp. 71-72 ◽  
Author(s):  
Dillon Mellick ◽  
Ana De Souza ◽  
Vanessa Iseri ◽  
Venkatesh Mani

Abstract Previous studies have shown that the inclusion of medium chain fatty acids (MCFA) results in an improvement in nursery pig performance. Therefore, the objective of this study was to evaluate a proprietary C8:C10 MCFA blend (CaptiSURE, Kemin Industries, Inc., Des Moines, IA) on nursery pig performance. A total of 360 weaned piglets (initial BW = 6.1 kg) were randomly assigned to a control (no MCFA blend) or 10 kg/t MCFA blend (10 pigs/pen, 18 replicate pens/treatment), in which MCFA blend was substituted at the expense of tallow at a 1:1 rate. Diets were manufactured in 3 dietary phases (d 0–7, 7–21, and 21–42) in pelleted form. Due to an unintended bacterial challenge at the sow farm, pigs were treated with amoxicillin using a pulse protocol (48 hrs on / 48 hrs off) from placement to d 21. Data were analyzed using the students T-test procedure, and pen served as the experimental unit. Within dietary phase 2 (d 7–21), the inclusion of MCFA blend improved ADG (264g vs 326g, P = 0.017) and G:F (0.79 vs 0.89, P = 0.005), while exhibiting a trend to improve ADFI (330g vs 364g, P = 0.080). Within dietary phase 3 (d 21–42), the inclusion of MCFA blend improved ADG (518g vs 581g, P = 0.024) and ADFI (719g vs 799g, P = 0.006). Overall (d 0–42), the inclusion of MCFA blend improved ADG (379g vs 438g, P = 0.007), ADFI (503g vs 0.562g, P = 0.009), and G:F (0.75 vs 0.78, P = 0.042), resulting in a 2 kg heavier pig (P = 0.043). In summary, the inclusion of a proprietary C8:C10 MCFA blend at 1.0% in nursery pig diets improved growth performance.


2001 ◽  
Vol 60 (4) ◽  
pp. 215-230 ◽  
Author(s):  
Jean-Léon Beauvois

After having been told they were free to accept or refuse, pupils aged 6–7 and 10–11 (tested individually) were led to agree to taste a soup that looked disgusting (phase 1: initial counter-motivational obligation). Before tasting the soup, they had to state what they thought about it. A week later, they were asked whether they wanted to try out some new needles that had supposedly been invented to make vaccinations less painful. Agreement or refusal to try was noted, along with the size of the needle chosen in case of agreement (phase 2: act generalization). The main findings included (1) a strong dissonance reduction effect in phase 1, especially for the younger children (rationalization), (2) a generalization effect in phase 2 (foot-in-the-door effect), and (3) a facilitatory effect on generalization of internal causal explanations about the initial agreement. The results are discussed in relation to the distinction between rationalization and internalization.


2018 ◽  
Vol 86 (08) ◽  
pp. 456-457
Keyword(s):  
Phase 2 ◽  
Phase 3 ◽  

Die Blockade von Serotoninrezeptoren, insbesondere des Serotonin-Rezeptortyps 5-HT6, als Zusatztherapie in Kombination mit Cholinesterasehemmer, hat in experimentellen Versuchen sowie in einer Phase-2-Studie positive Effekte bei Demenz gezeigt. Im Rahmen eines Phase-3 Entwicklungsprogramms wurde nun die Effektivität des selektiven Serotoninrezeptor-Antagonisten Idalopirdin bei leichter bis mittelschwerer Alzheimer Demenz geprüft.


Pneumologie ◽  
2013 ◽  
Vol 67 (S 01) ◽  
Author(s):  
M Steinmaurer ◽  
N Mürzl ◽  
H Feizelmeier ◽  
J Eckmayr ◽  
V Radulovic
Keyword(s):  

Pneumologie ◽  
2016 ◽  
Vol 70 (S 01) ◽  
Author(s):  
M Steinmaurer ◽  
P Vinatzer ◽  
N Mürzl ◽  
J Eckmayr
Keyword(s):  

Pneumologie ◽  
2016 ◽  
Vol 70 (10) ◽  
Author(s):  
K Olivier ◽  
D Griffith ◽  
K Winthrop ◽  
B Brown-Elliott ◽  
G Eagle ◽  
...  
Keyword(s):  
Phase 2 ◽  

2017 ◽  
Vol 08 (04) ◽  
pp. 188-189
Author(s):  
Katharina Arnheim
Keyword(s):  
Phase 2 ◽  

Auch bei Patienten mit malignem Pleuramesotheliom (MPM) könnte die Immuntherapie künftig für eine verbesserte Prognose sorgen: Erste Daten der noch laufenden Phase-2-Studie MAPS-2 mit Nivolumab und Ipilimumab machen Hoffnung.


Sign in / Sign up

Export Citation Format

Share Document